Accelr8 Shares More Than Double in February to Lead GWDN Index

Mar 02, 2011

NEW YORK (GenomeWeb News) – Shares Accelr8 more than doubled in the month of February, as the firm disclosed mid-month that its technology evaluation agreement with Novartis Vaccines and Diagnostics has been extended to June 30, 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

The Apple's Journey

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

This Week in Nature

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Change Is Hard to Do

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

Possible Paths for CUP

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

Main menu